Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Scott Daniels

Showing results (41-50 of 122) with videos related to

Pageof 13
Sort By:
Prostaglandins & Other Lipid Mediators|July 6, 2019
The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesityRyan P Ceddia, Jason D Downey, Ryan D Morrison, et al.
ACS Chemical Neuroscience|July 12, 2017
Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel ActivatorsJoshua M Wieting, Anish K Vadukoot, Swagat Sharma, et al.
Journal of Medicinal Chemistry|May 31, 2013
Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM)Cody J Wenthur, Ryan Morrison, Andrew S Felts, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2014
Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based leadCarrie K Jones, Douglas J Sheffler, Richard Williams, et al.
Bioorganic & Medicinal Chemistry Letters|April 30, 2018
Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5Andrew S Felts, Alice L Rodriguez, Ryan D Morrison, et al.
Chemical Research in Toxicology|October 18, 2007
Species-specific, P450- and sulfotransferase-mediated novel ring contraction of a naphthyridine-N-oxide compound in cynomolgus monkeyJ Scott Daniels, Robert Espina, Kevin Cao, et al.
ACS Chemical Neuroscience|January 7, 2015
Identification and characterization of ML352: a novel, noncompetitive inhibitor of the presynaptic choline transporterElizabeth A Ennis, Jane Wright, Cassandra L Retzlaff, et al.
Plos One|September 29, 2017
Medication adherence, medical record accuracy, and medication exposure in real-world patients using comprehensive medication monitoringTimothy P Ryan, Ryan D Morrison, Jeffrey J Sutherland, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2014
Further optimization of the M5 NAM MLPCN probe ML375: tactics and challengesHaruto Kurata, Patrick R Gentry, Masaya Kokubo, et al.
Journal of the American Geriatrics Society|September 11, 2019
Supratherapeutic Psychotropic Drug Levels in the Emergency Department and Their Association with Delirium Duration: A Preliminary StudyJin H Han, Alex Chen, Eduard E Vasilevskis, et al.
Pageof 13

Showing results (41-50 of 122) with videos related to

Sort By:
Pageof 13
Prostaglandins & Other Lipid Mediators|July 6, 2019
The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesityRyan P Ceddia, Jason D Downey, Ryan D Morrison, et al.
ACS Chemical Neuroscience|July 12, 2017
Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel ActivatorsJoshua M Wieting, Anish K Vadukoot, Swagat Sharma, et al.
Journal of Medicinal Chemistry|May 31, 2013
Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM)Cody J Wenthur, Ryan Morrison, Andrew S Felts, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2014
Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based leadCarrie K Jones, Douglas J Sheffler, Richard Williams, et al.
Bioorganic & Medicinal Chemistry Letters|April 30, 2018
Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5Andrew S Felts, Alice L Rodriguez, Ryan D Morrison, et al.
Chemical Research in Toxicology|October 18, 2007
Species-specific, P450- and sulfotransferase-mediated novel ring contraction of a naphthyridine-N-oxide compound in cynomolgus monkeyJ Scott Daniels, Robert Espina, Kevin Cao, et al.
ACS Chemical Neuroscience|January 7, 2015
Identification and characterization of ML352: a novel, noncompetitive inhibitor of the presynaptic choline transporterElizabeth A Ennis, Jane Wright, Cassandra L Retzlaff, et al.
Plos One|September 29, 2017
Medication adherence, medical record accuracy, and medication exposure in real-world patients using comprehensive medication monitoringTimothy P Ryan, Ryan D Morrison, Jeffrey J Sutherland, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2014
Further optimization of the M5 NAM MLPCN probe ML375: tactics and challengesHaruto Kurata, Patrick R Gentry, Masaya Kokubo, et al.
Journal of the American Geriatrics Society|September 11, 2019
Supratherapeutic Psychotropic Drug Levels in the Emergency Department and Their Association with Delirium Duration: A Preliminary StudyJin H Han, Alex Chen, Eduard E Vasilevskis, et al.
Pageof 13